-+ 0.00%
-+ 0.00%
-+ 0.00%

argenx Highlights 2026 Strategic Priorities As Q4 Sales Reach $1.29B And Preliminary 2025 Net Sales Total $4.15B

Benzinga·01/12/2026 06:32:22
Listen to the news
  • Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales
  • VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026
  • Four registrational readouts expected in 2026, including first for empasiprubart, to advance toward next wave of 2027 commercial launches
  • Successfully advanced four new pipeline molecules in 2025; three new molecules to enter Phase 1 in 2026, contributing to total of 10 clinical-stage molecules by year-end